BioNxt Solutions Inc.
BNXT
CNSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -53.04% | 99.05% | |||
| Depreciation & Amortization | 219.51% | -125.15% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -38.66% | 66.05% | |||
| Operating Income | 38.66% | -66.77% | |||
| Income Before Tax | 31.69% | -38.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 31.69% | -48.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 31.69% | -48.45% | |||
| EBIT | 38.66% | -66.77% | |||
| EBITDA | 38.27% | -68.26% | |||
| EPS Basic | 31.93% | -45.12% | |||
| Normalized Basic EPS | 27.54% | -23.21% | |||
| EPS Diluted | 31.93% | -45.12% | |||
| Normalized Diluted EPS | 27.54% | -23.21% | |||
| Average Basic Shares Outstanding | 0.61% | 1.75% | |||
| Average Diluted Shares Outstanding | 0.61% | 1.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||